” We are excited to now be dealing with Memorial Sloan Kettering Cancer Center and Nationwide Childrens Hospital to more establish our lead cancer drug candidate Seclidemstat as a possible treatment for Ewing sarcoma,” specified David Arthur, President and Chief Executive Officer of Salarius. “Ewing sarcoma is a disastrous and uncommon pediatric bone and soft-tissue cancer for which there are no targeted treatments currently available. We believe Seclidemstat could have a significant effect in Ewing sarcoma as a possible new and less hazardous treatment, benefitting patients and their households.”
The Company has 3.64 million shares outstanding and 2.6 million shares were drifted in market. 2.10% ownership is held by institutional investors while insiders hold ownership of 0.50%.
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) stayed amongst the day gainers losers and traded with modification of -7.32% on volume of 20533 shares in the last session as compared to average volume of 35132 shares. During last trade its minimum price was $5.02 and it gained highest price of $5.53. SLRX has overall market capitalization of $19447900. Its closing worth stands at $5.19.
Salarius Pharmaceuticals, Inc. (SLRX) reported just recently that Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Nationwide Childrens Hospital (Nationwide Childrens) in Columbus, OH have actually been included as scientific trial sites in the continuous Phase 1/2 scientific trial of Seclidemstat for the treatment of Ewing sarcoma. The addition of MSKCC and Nationwide Childrens brings the total number of active medical trial sites to eight.